Podcasts about autoantibodies

In today’s talk, we are going to learn about the translational value of one of the largest randomised controlled trials of subclinical hypothyroidism in homeopathy. This study was published in the year 2014. This was a two-part study. In the 1st part, we had the epidemiological screening in which we screened more than 5000 schoolchildren of Delhi between the ages of 6 and 18 years, and they were subjected to the biochemical investigations, including FT3, FT4, TSH, anti-TPO antibodies and ultrasound of the thyroid gland. So once the epidemiological phase was over, we entered into the phase of clinical trial. So, here we are going to deduce the 6 most important thyroid tips. Watch on Youtube Tip Number 1: Subclinical does not mean undetectable. Many times it happens that patients don’t have symptoms. And don’t want to have the investigation done. But what if they have mild symptoms? What if they have a family history of thyroid disorders? What if you have a suspicion? Always and always go for the basic routine investigations. Once we routinely screened more than 5000 schoolchildren in Delhi, we found that 613 kids had problems. And it’s not a small number. At that time, the prevalence rate used to be 6-8%, as reported by different agencies, and we found that it was more than 10%. Out of those 613, seventy-six had to be referred to an endocrinologist for further evaluation because they had symptoms, and their thyroid index was beyond the inclusion criteria. And their symptoms were ignored. Since we screened them, they were picked up. We found that 35% of the kids have mild to moderate symptoms which can be referred to as common symptoms in clinical practice, such as poor concentration, hairball, lack of interest in the studies, headaches, fatigue, and tiredness. weight gain or even dry hairs. Tip Number 2: Autoantibodies are the warning light for progression. We observed that at various places where even the FT3, FT4 and TSH were all within normal limits, their anti-TPO antibodies were raised. This is direct evidence of the autoimmunity, and it starts like this only. At this stage, you can correlate these findings with the theory of miasms. Once they are in a psoric state, there may not be any symptoms, but there may be alterations. Once these alterations set in, they typically progress to further states, which may include overt hypothyroidism over the course of years. So, these thyroid antibodies act like a radar for early detection of these symptoms. In the study control group, 10.5% of the children went into overt hypothyroidism over the 18-month duration of the treatment. But none of the children in the homoeopathic group developed any problems. And those who developed the problem shared two common factors. Either they had the elevated anti-TPO antibodies or their family history was positive for the thyroid disorders. Tip Number 3: it is always about individualisation. In our study, the individualised care showed a promising biochemical response. Over the 18 months of study, 85% of the kids on homeopathic treatment showed normalcy in their TSH levels. In comparison to 64%, which was in the study control group. The recovery in the homeopathic group was more clinically relevant, and it was without any problems. In addition, we saw that 70% of the kids who were autoantibody positive returned to normalcy, compared to 27% of the kids who did not receive the medicines. So additionally, 70% of the kids were treated in comparison to the control group with homeopathy. So the result was huge clinical as well as statistically significant data. Tip Number 4: There is no perfect magical thyroid pill. In our study, we offered the individualised constitutional treatment to the kids, but we did encounter certain frequently used and most indicated remedies: Natrum mur, Calcarea carb, Pulsatilla, etc. Tip Number 5: Regular monitoring is non-negotiable. Don’t rely on one report. In our study too. We cross-checked each and every investigation and sample. And whenever there was any confusion, we repeated those tests. Just to reduce the errors and bias. In the clinical practice too, many times you may encounter a patient who needs repetition in terms of the investigations; always do that. Never ever treat a patient with a suspicion. Always and always make a nosological diagnosis, clear the doubts, and then start treating those patients. The study monitored the serum FT3, FT4, TSH and anti-TPO antibodies at regular intervals in the whole 18 months of duration of the treatment. And that is the reason we could correlate it statistically because we had a series of readings, and we tried to reduce the bias. Tip number 6: Know when the intervention is essential. Clinical trial protocols are to be followed religiously and ethically. In our study too, we had clear-cut inclusion and exclusion criteria, and we followed these criteria throughout the study. There should be a clear line of treatment drawn in such patients. The study strictly enforced the… clinical endpoint. and that was TSH greater than 10. Whenever there is overt hypothyroidism, the case should be referred to an expert for the analysis and evaluation. So this study taught us many things. This study taught us how to enter the epidemiological phase, how to correlate the findings of the epidemiological phase with the clinical trial, and what to do and what not to do in the clinical setting. Although they were part of the research, I think we can practise these clinical findings and keep these clinical findings and learning insights in mind. Then our practice in thyroid disorders would be more ethical, and it would be more logical and intellectual. Disclaimer: The content of this podcast, including text, graphics, images, or any other material, is for informational purposes only and not a substitute for professional and expert advice.” Listen to the podcast below The post 6 most Important Thyroid Tips [Podcast] appeared first on Dr Saurav Arora.

Could a mother's immune system hold key clues to fetal brain development? Dr. Jovana Lubarda interviews Dr. Judy Van de Water, Dr. Melissa Bauman, and advocate Laura Cellini to explore maternal autoantibody–related autism (MAR), translational science, and the future of precision medicine. This podcast is not available for CME/CE/CPD credits. Please visit the Medscape homepage for accredited CME/CE/CPD activities.

In this episode, Dr. Steve Edelman and Dr. Jeremy Pettus are joined by Dr. Shara Bialo, Senior Medical Director of Type 1 Diabetes Immunology at Sanofi, pediatric endocrinologist, and person living with type 1 diabetes, for an in-depth discussion about what happens before type 1 diabetes is diagnosed. Together, they explore the autoimmune process that begins months or even years before symptoms appear, why early detection matters, and how screening is changing the future of type 1 diabetes care. Dr. Bialo shares her personal diagnosis story, discusses common misconceptions about what causes type 1 diabetes, and explains the three stages of the disease. The conversation also covers who should be screened, how diabetes autoantibody testing works, the benefits of preserving beta cell function, and why identifying people before they develop symptoms can lead to better long-term outcomes and fewer cases of diabetic ketoacidosis (DKA). Whether you have type 1 diabetes, have a family member at risk, or simply want to better understand the latest advances in prevention and early detection, this episode provides valuable insights into one of the fastest-moving areas of diabetes research.Key Topics:Dr. Shara Bialo's personal journey living with type 1 diabetesWhy type 1 diabetes is an autoimmune disease, not simply a blood sugar problemThe role of genetics, viral infections, and the immune systemUnderstanding the three stages of type 1 diabetesWhy most people diagnosed with type 1 diabetes have no family historyAdult-onset type 1 diabetes and why it is often mistaken for type 2 diabetesWhat diabetes autoantibodies are and how screening worksWho should consider screening for type 1 diabetesAvailable screening options, including blood tests and home screening kitsThe emotional challenges families face when considering screeningThe importance of preventing diabetic ketoacidosis through early detectionWhy preserving beta cell function can improve long-term outcomesItaly's national screening program and the future of population-wide screeningResources available through screenfortype1.comThis content was produced with support from Sanofi and screenfortype1.com.✨ Subscribe for practical diabetes management tips, technology updates, and treatment breakthroughs that help people with diabetes live healthier, more flexible lives.More diabetes resources:Website: tcoyd.orgBlog: tcoyd.org/blogPodcast: tcoydthepodcast.transistor.fmInstagram:   / tcoydFacebook:   / tcoydStay connected! Sign up for our monthly newsletter here!Support TCOYD's educational programs: tcoyd.org/donate ★ Support this podcast ★

Send comments and feedbackWhat is autoimmune-associated epilepsy, and how is it different from acute seizures with an autoimmune cause? How can clinicians best diagnose and treat these conditions? Sharp Waves reporter Dr. Maryam Nabavi-Nouri spoke with Dr. Claude Steriade.Claude Steriade, MD, CM is originally from Quebec City, Canada. She completed medical school at McGill University in Montreal, followed by an adult neurology residency at the University of Toronto. Dr. Steriade then completed a two-year epilepsy fellowship at the Cleveland Clinic before joining the epilepsy center at New York University. Relevant articles:Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitionsDiscerning the Role of Autoimmunity and Autoantibodies in Epilepsy: A Review --This episode was reported by Dr. Maryam Nabavi-Nouri, and edited and produced by Nancy Volkers. Sharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.Let us know how we're doing:  info@ilae.orgThe International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Instagram, and LinkedIn.

Summary In this episode of the Future of Dermatology podcast, guest speaker Dr. Donna Culton, delves into the intricate science of skin diseases, focusing on the pathophysiology of conditions like pemphigoid. The discussion covers the roles of B cells, autoantibodies, and various cellular players in inflammation, as well as the mediators that contribute to symptoms like itch. The episode emphasizes the complexity of these diseases and the potential for new therapeutic targets, while also highlighting the challenges in conducting clinical trials for affected populations. Takeaways - Dr. Culton emphasizes the importance of understanding B cells in skin diseases. - Pemphigus and pemphigoid have distinct clinical presentations and treatments. - Autoantibodies play a crucial role in the pathophysiology of pemphigoid. - Mast cells and eosinophils are key players in the inflammatory response. - Cytokines like IL-4 and IL-5 are critical for B cell activation and eosinophil recruitment. - The itch associated with pemphigoid is complex and not solely due to histamine. - Clinical trials for skin diseases face unique challenges due to patient comorbidities. - Understanding the mediators of degradation can inform treatment strategies. - The complexity of skin diseases allows for multiple therapeutic targets. - This podcast serves as an educational resource for understanding dermatological science. Chapters 00:00 - Introduction to Dermatology and B Cells 02:51 - Understanding Pemphigus and Pemphigoid 05:25 - The Role of Autoantibodies in Skin Diseases 08:20 - Key Cellular Players in Inflammation 10:53 - Mediators of Inflammation and Itch 13:57 - Pathophysiology and Future Therapies

In part two of this two-part series, Dr. Stacey Clardy and Dr. Elia Sechi discuss how to approach the management of patients in clinic when there is concern for a possible false positive on the radioimmunoprecipitation assay for the acetylcholine receptor antibody. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213498 

In part one of this two-part series, Dr. Stacey Clardy and Dr. Elia Sechi discuss the clinical scenarios where the commonly used assay for myasthenia gravis is most likely to produce false positive results in patients who do not actually have myasthenia gravis. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000213498  

Dr. Stacey Clardy talks with Dr. Elia Sechi about the importance of understanding lab test results, the performance characteristics of assays, and the real-world implications of false positives in myasthenia gravis testing. Read the related article in Neurology®. Disclosures can be found at Neurology.org. 

Dr. Prem Premsrirut is the Executive Director and CEO of Micoy Therapeutics, a pioneering biotech company dedicated to combating autoantibodies that transform common illnesses into life-threatening diseases. In this episode, KJ and Dr. Prem discuss the importance of understanding the immune system, the challenges of current diagnostic methods for autoimmune diseases, and the potential future of healthcare driven by innovative research. Key Highlights: 03:46 The Fascination with the Human Body and Disease Prevention 04:39 Exploring Autoantibodies and Autoimmune Diseases 08:50 The Impact of COVID-19 on Autoimmune Research 11:48 The Role of Autoantibodies in Viral Infections 25:03 The Future of Healthcare and AI Quote of the Show (29:00): “Your body is fascinating. It's dynamic, and it's about preventing what tries to take that resilience away.” - Dr. Prem Premsrirut Join our Anti-PR newsletter where we’re keeping a watchful and clever eye on PR trends, PR fails, and interesting news in tech so you don't have to. You're welcome. Want PR that actually matters? Get 30 minutes of expert advice in a fast-paced, zero-nonsense session from Karla Jo Helms, a veteran Crisis PR and Anti-PR Strategist who knows how to tell your story in the best possible light and get the exposure you need to disrupt your industry. Click here to book your call: https://info.jotopr.com/free-anti-pr-eval Ways to connect with Dr. Prem Premsrirut: LinkedIn https://www.linkedin.com/in/prem-premsrirut-36220125/ Company website https://www.micoytherapeutics.com/ How to get more Disruption/Interruption: Amazon Music - https://music.amazon.com/podcasts/eccda84d-4d5b-4c52-ba54-7fd8af3cbe87/disruption-interruption Apple Podcast - https://podcasts.apple.com/us/podcast/disruption-interruption/id1581985755 Spotify - https://open.spotify.com/show/6yGSwcSp8J354awJkCmJlDSee omnystudio.com/listener for privacy information.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-explained-anti-achr-anti-musk-and-their-diagnostic-role/32728/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-explained-anti-achr-anti-musk-and-their-diagnostic-role/32728/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

In today's episode of The Root Cause Medicine Podcast, Dr. Carrie Jones sits down with Dr. Elroy Vojdani, an expert in autoimmune diseases and author of the book “When Food Bites Back,” to dive deep into the rising prevalence of autoimmune conditions and how lifestyle factors like diet, sleep, and stress management may play a role in supporting overall immune health. You'll hear them discuss: The alarming increase in autoimmune diseases over the past two decades Common autoimmune diseases Environmental triggers of autoimmunity Lab tests for autoimmune disease The importance of diet, sleep, movement, and stress management in addressing autoimmune conditions With a rich background in both scientific research and traditional medicine, Dr. Elroy has dedicated his career to understanding the complexities of autoimmunity, particularly the environmental and genetic factors that contribute to its rise. Dr. Elroy uses his medical training and knowledge, along with state-of-the-art lab testing and scientifically proven methods, to accurately diagnose and develop personalized wellness strategies based on lab testing and functional medicine principles to support overall health and well-being. Order tests through Rupa Health, a resource for functional medicine lab tests from 30+ labs. Speak with your healthcare provider to determine which tests may be most appropriate for you - https://www.rupahealth.com/reference-guide

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-in-mg-their-role-in-diagnosis-and-treatment/32239/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

CME credits: 1.00 Valid until: 17-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-in-mg-their-role-in-diagnosis-and-treatment/32239/ The burden of generalized myasthenia gravis (gMG) on patients and caregivers is substantial. Current traditional therapies are often effective in the short term but bring with them many debilitating side effects. A more targeted approach to treatment that focuses on inhibition of the neonatal FcRn receptor complex is offering an exciting and different treatment option. Join Drs. Nicholas Silvestri and James Howard, Jr, as they discuss the expanding landscape of gMG treatments.

Immune discusses basophils as regulators of of lung inflammation over space and time, and neoself-antigens as the primary target for autoreactive T cells in human lupus. Hosts: Vincent Racaniello, Cindy Leifer, Steph Langel, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server Basophils promote asthma (J Exp Med) Basophils regulate lung inflammation (J Exp Med) Neoself antigens are primary T cell targets in lupus (Cell) Time stamps by Jolene. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv

In this episode Dr. Kharrazian explores the world of chronic infections, such as Epstein-Barr Virus (EBV), Hepatitis C, Covid, and Human Cytomegalovirus (CMV), and their impact on our immune system. He explores how some pathogens hide within our bodies and reemerge when our immunity is compromised.He discusses the latest research linking these infections to autoimmune diseases and even cancer, and emphasizes the importance of enhancing our immune defenses rather than just relying on antiviral treatments. He covers a wide range of topics from the basics of virology, the dynamics of long COVID, and the sobering realities of Hepatitis C and Human Papillomavirus (HPV), to the ripple effects of viral infections on our overall health.Learn more at drknews.comFor patient-oriented courses, visit https://drknews.com/online-courses/For CE and CME practitioner courses, visit https://kharrazianinstitute.com/00:00 MHC proteins activate cells to fight infection.06:16 Long COVID factors: comorbidities, age, severity, inflammation, genetics13:50 Viral infection can trigger chronic inflammatory conditions.17:27 Long COVID linked to persistent antinuclear antibodies.22:53 Autoantibodies may form due to SARS-CoV-2 infection.27:28 Hepatitis B virus vaccine increases MS risk.33:58 Alphaviruses include herpes, 53% exhibit antibodies.39:30 Cytomegalovirus linked to autoimmune diseases, immune manipulation.45:39 Chronic Epstein Barr causes inflammation, cancer risk.52:02 Hepatitis C symptoms: diverse and system-wide impacts.57:33 High treatment costs spark global protests, denials.01:00:33 PCR measures viral load; biomarkers assess liver damage.01:06:08 Identify underlying health issues causing recurring infections.Support this show http://supporter.acast.com/solving-the-puzzle-with-dr-datis-kharrazian. Hosted on Acast. See acast.com/privacy for more information.

Autoimmunity and autoimmune diseases are on the rise. In this episode I look at why this is the case, the mechanisms behind autoimmunity and what we can do to prevent and manage it.Innate vs adaptive immunity (including B and T cells): https://www.ncbi.nlm.nih.gov/books/NBK279396/#Molecular mimicry in autoimmunity: https://www.sciencedirect.com/science/article/pii/S0896841118305365#Hashimoto's - molecular mimicry in action. Gluten mimics the surface proteins of the thyroid gland: https://pubmed.ncbi.nlm.nih.gov/37554764/Autoantibodies: https://pathology.jhu.edu/autoimmune/definitionsThe rise of autoimmunity and autoimmune diseases: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918670/#Intestinal permeability and autoimmunity: https://academic.oup.com/biohorizons/article/doi/10.1093/biohorizons/hzx015/4670557#'Leaky gut' syndrome: https://www.medicalnewstoday.com/articles/326117Autoimmune protocol diet: https://www.healthline.com/nutrition/aip-diet-autoimmune-protocol-diet#how-it-worksProteus and rheumatoid arthritis; https://www.iomcworld.org/open-access/worldwide-links-between-emproteus-mirabilisem-and-rheumatoid-arthritis-46162.htmlSleep and autoimmunity: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00311-3/fulltextStress and autoimmunity: https://www.autoimmuneinstitute.org/articles/stress-autoimmune-disease-navigating-the-complex-relationship/An expert opinion on the rise in autoimmunity: https://medicine.yale.edu/news-article/why-are-autoimmune-and-allergic-diseases-rising-andrew-wang/Vitamin D and autoimmunity: https://www.newscientist.com/article/2306132-vitamin-d-supplements-really-do-reduce-risk-of-autoimmune-disease/#ixzz7KF2W0SEL Hosted on Acast. See acast.com/privacy for more information.

David Liew talks to rheumatologist Nicola Cook about the utility of common investigations for suspected inflammatory arthritis in adults. They discuss the notion of pretest probability and how this is used to determine the utility of testing, and the role of specific tests. Nicola also talks about the potential harm of overinvestigation. Read the full article by Nicola and her co-author, Rachelle Buchbinder, in Australian Prescriber.

In this episode, we review the high-yield topic of⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Autoantibodies in Autoimmune Disease⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the MSK section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis

Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis

Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis

Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis

Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis

Nils Erik Gilhus, MD, PhD - Disruption at the Neuromuscular Junction: Relevance of Autoantibodies to Therapy in Generalised Myasthenia Gravis

In this week's episode, Jonathan is joined by Stephanie Hanna, a Research Fellow for the Diabetes Research and Wellness Foundation, in the Division of Infection and Immunity, at Cardiff University's School of Medicine, Wales, UK. In this fascinating episode, the pair discuss all things diabetes, including immunotherapy, the future of diagnosis, and how to predict your diabetes risk. Use the following timestamps to navigate the content in this episode:  (00:00)-Introduction (01:22)-Getting into Type 1 diabetes (T1D) (02:23)-Stages of T1D (05:04)-Biomarkers of T1D (07:01)-Phenotypic analysis of T and B-cells (08:24)-Diabetes progression (10:11)-Immunotherapy for T1D (14:00)-Challenges in measuring immune response (16:22)-Some thoughts on artificial intelligence (18:11)-How to get involved in a study (19:27)-Checking your own antibody status (23:51)-Thyroid eye disease (25:19)-Risks of overlooking T1D (27:34)-Three wishes for the future of healthcare

1. Understand the ways to screen for T1D risk (Autoantibodies).2. Be aware of the currently FDA approved therapies to prevent/delay T1D progression.3. Refer potential subjects for participation in T1D research studies.**please add the below exam questions for CE credits: 1. More than 90% of newly diagnosed patients with type 1 diabetes do NOT have a first degree family member with type 1 diabetes (T/F) - answer True2. Type 1 diabetes can be delayed with the use of an FDA approved immunotherapy (T/F) - answer True3. Which autoantibodies can be used to detect T1DGADAIAAIA2AZnT8AICAAnswer - all of the above

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: July 18, 2017 Myasthenia gravis is a disorder characterized by proximal weakness, ptosis, and antibody formation against proteins at the neuromuscular junction. Most commonly, the protein targeted by antibodies is the nicotinic acetylcholine receptor. However, research in the last 2 decades has identified a number of other antibody targets, which we have reviewed here in this BrainWaves brief. BrainWaves podcasts and online content are intended for medical education only and should not be used to guide medical decision-making in routine clinical practice. Any cases discussed in this episode are fictional and do not contain any patient health-identifying information. The content in this episode was vetted and approved by Grant T Liu. REFERENCES Dalmau J, Rosenfeld MR. Paraneoplastic syndromes of the CNS. Lancet Neurol 2008;7(4):327-40. PMID 18339348Evoli A, Lancaster E. Paraneoplastic disorders in thymoma patients. J Thorac Oncol 2014;9(9 Suppl 2):S143-7. PMID 25396312Gilhus NE, Verschuuren JJ. Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 2015;14(10):1023-36. PMID 26376969Hurst RL, Gooch CL. Muscle-specific receptor tyrosine kinase (MuSK) myasthenia gravis. Curr Neurol Neurosci Rep 2016;16(7):61. PMID 27170368Koneczny I, Cossins J, Vincent A. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis. J Anat 2014;224(1):29-35. PMID 23458718 We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

Hello bug lovers! Today, we're guided by Mike Skvarla into a deep dive on West Nile virus. A mosquito borne illness, West Nile is something the Arthro-Pod crew has learned a lot about over the course of their lives and careers. In fact, one of them even tested positive for it after trying to give blood... Mike was inspired by Episode 1031 of the This Week in Virology podcast, where they discussed a recent paper on the subject. The paper is “Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients”, by Gervais et al. published in the Journal of Experimental Medicine. Tune in to learn about the history of WNV and the current research focused on it. The virus of concernQuestions? Comments? Follow the show on Twitter @Arthro_PodshowFollow the hosts on Twitter @bugmanjon, @JodyBugsmeUNL, and @MSkvarla36Get the show through Apple Podcast, Spotify, or your favorite podcatching app!If you can spare a moment, we appreciate when you subscribe to the show on those apps or when you take time to leave a review!Subscribe to our feed on Feedburner!  

References Journal of Immunology Research Article ID 8263829 JAMA. 2021 Jun 15; 325(23): 2392–2393. Thyroid. 2014 Feb 1; 24(2): 371–382. Pol Arch Intern Med. 2022 Mar 30; 132(3): 16222. FEBS Letters.1997. (414): 258-262 --- Send in a voice message: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/message Support this podcast: https://podcasters.spotify.com/pod/show/dr-daniel-j-guerra/support

Host Roz is joined by AJT Editorial Board Member Kenneth Newell, MD, PhD (Emory University) and AJT Editorial Fellow Kyle Jackson, MD, PhD (Emory University) [2:45] Identifying and understanding variation in population-based access to liver transplantation in the United States [12:44] Intra-graft B cell differentiation during the development of tolerance to kidney allografts is associated with a regulatory B cell signature revealed by single cell transcriptomics [18:21] Single-cell RNA sequencing reveals peripheral blood mononuclear immune cell landscape associated with operational tolerance in a kidney transplant recipient [22:20] Impact of allele-specific anti-HLA class I antibodies on organ allocation [28:12] Autoantibodies against DNA-topoisomerase I promote renal allograft rejection by increasing alloreactive T cell responses

Welcome to the 12th episode of The Brain Podcast - the official podcast of the journals Brain and Brain Communications.  In this episode we speak with Nico Melzer, senior author of the article entitled: A genome-wide association study in autoimmune neurological syndromes with anti-GAD65 autoantibodies This article explores expanding entity of GAD-65 associated neurological syndromes, the exciting role of T-cells and potential therapeutic avenues that these findings may bring.  Check out the full article on the Brain website: https://doi.org/10.1093/brain/awac119 This episode was co-hosted by Adam Handel and Darshan Pandya , edited and produced by Adam Handel and Xin You Tai; co-produced by Antonia Johnston; original music by Ammar Al-Chalabi.

TWiV notes the passing of virologist Michael BA Oldstone, a study to assess the performance of rapid antigen tests to detect symptomatic and asymptomatic SARS-CoV-2 infection, and the presence of antibodies to type I interferons in ~40% of patients with West Nile virus encephalitis. Hosts: Vincent Racaniello, Rich Condit, and Alan Dove Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode MicrobeTV Discord Server MicrobeTV store at Cafepress Position in Rosenfeld Laboratory (pdf) XKCD on antivaxxers RFK Jr. CDC or FDA head? (Politico) Performance of rapid antigen tests (Ann Int Med) Guidance on rapid antigen tests (FDA) Autoantibodies to IFN in West Nile virus encephalitis (JEM) Letters read on TWiV 1031 Timestamps by Jolene. Thanks! Weekly Picks Rich – The Final Covid-19 Grand Rounds: What Have We Learned? Alan – Teaching biology to Tibetan Buddhist monks Vincent – I got it from Agnes by Tom Lehrer and Why Oppenheimer has important lessons for scientists today Listener Picks Ryan – Paul Offit on PBS Newshour to explain RFK Jr.'s Congressional Hearing Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

The ANA, anti-CCP, RF, and beyond! We all have ‘rheum' to grow when it comes to making sense of autoantibodies and common markers. We talk through the nuances with rheumatologist Dr. Matthew B. Carroll (biography here!). Our interview covers physical exam tips for inflammatory arthritis, basic interpretation of rheumatologic testing, and what to do with the dreaded ‘vaguely positive' speckled ANA! Claim free CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Intro Case 1 History clues Physical exam pearls; what does synovitis look like? Interpreting mixed labs Rheumatoid Factor tips Role for imaging Importance of early diagnosis New testing modalities Case 2 Oh no– a vaguely positive ANA! ANA testing basics Outro Credits Showrunners, Hosts, Producers and Writers: Matthew Watto MD, FACP; Paul Williams MD, FACP    Show Notes, Infographic, Cover Art: Beth Garbitelli MD Reviewer: Emi Okamoto MD  Technical Production: PodPaste Guest: Matthew B. Carroll MD Sponsor: Brooklinen Visit Brooklinen.com today and get $20 off plus free shipping on orders of $100+ with code [CURB] Sponsor: Grammarly Go to grammarly.com/tone to download and learn more about Grammarly Premium's advanced tone suggestions. Sponsor: Glass Health You can get one month of Glass Pro free by signing up at glass.health and using the code: CURBSIDERS.

Junjie from Jason's lab joins TWiN to discuss the observation that the cell gene PNMA2 encodes non-enveloped virus-like capsids that induce autoantibodies which underlie paraneoplastic syndrome. Hosts: Vincent Racaniello, Jason Shepherd, Timothy Cheung, and Junjie Xu Subscribe (free): Apple Podcasts, Google Podcasts, RSS Links for this episode MicrobeTV Discord Server Virus-like capsids in paraneoplastic disease (bioRxiv) Timestamps by Jolene. Thanks! Music is by Ronald Jenkees Send your neuroscience questions and comments to twin@microbe.tv

TWiV reveals how treatment with remdesivir for COVID-19 resolved a chronic poliovirus infection in an immunocompromised patient, and the finding that infection with SARS-CoV-2 leads to an increase in new and preexisting autoantibodies. Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode •Register for ASV 2023 •MicrobeTV Discord Server •Janet Sinsheimer on TWiV 653 •Clearance of chronic poliovirus infection by remdesivir (Front Immunol) •Autoimmunity induced by SARS-CoV-2 infection (Nat Comm) •Letters read on TWiV 993 •Timestamps by Jolene. Thanks! Weekly Picks Brianne – Xkcd: Lymphocytes Kathy – A brief history of Parafilm with video Alan – Mapping and exploring the USS Monitor wreck Vincent – Skype a Scientist Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Did you know that there are now over 80 different types of autoimmune diseases that impact multiple organs, tissues, cells and compounds such as enzymes in the body? An autoimmune disease occurs when your body's own immune system starts to attack itself, and as a result of this attack, it causes damage to the body leading to disease.Classifying different autoimmune diseases is no mean feat and requires scrutiny of your symptoms, biochemistry and whether the condition is organ-specific and systemic. And that is why many conditions that we don't class as autoimmune in nature could, in fact, have an element of autoimmunity. One such condition is polycystic ovarian syndrome (PCOS) which I repeatedly see in my clinical practice with my clients living with autoimmune diseases. This led me to investigate some similarities between these conditions and even to question, is PCOS an autoimmune disease?In this episode we will explore the link between autoimmune disease and PCOS and how addressing the root cause may help with symptoms of both conditions. Highlight's from today's episode include:What is PCOS?Autoantibodies and how they affect your body. Insulin resistance and blood sugar dysregulation in PCOS and autoimmune disease.Chronic inflammation in autoimmune disease and PCOS.Do you think PCOS is an autoimmune disease? You can also read my article, 'Is polycystic ovarian syndrome an autoimmune disease?'Tune in today and be sure to share any of your thoughts about the show on my Instagram page: @theautoimmunitynutritionistYou can also download a free copy of The Autoimmunity Recovery Plan here.Book your free discovery call with me here.And if you would like to join my community of strong-willed people thriving with autoimmune disease, join The Autoimmunity Community. Thanks for listening! You can join The Autoimmunity Community on Facebook or find me on Instagram @theautoimmunitynutritionist.Thanks for listening! You can join The Autoimmunity Community on Facebook or find me on Instagram @theautoimmunitynutritionist.

Autoantibodies against post-translationally modified proteins (PTM) are described in various rheumatic diseases and facilitate diagnosis and patient stratification. Researchers from the Leiden University Medical Center analysed the presence of autoantibodies against six different post-translational modifications in a cohort of patients with neuropsychiatric lupus. In this podcast, Leendert Trouw, Rory Monahan and Michelle van den Beukel discuss the results of their study with the ARD/RMDopen social media advisor Caroline Ospelt. Read the Open Access related paper: https://rmdopen.bmj.com/content/8/1/e002079 Listen to more episodes of RMD Open: https://podcasts.apple.com/gb/podcast/rmd-open-rheumatic-and-musculoskeletal-diseases/id1237127864

CME credits: 0.50 Valid until: 10-01-2024 Claim your CME credit at https://reachmd.com/programs/cme/testing-and-screening-for-type-1-diabetes-t1d-genes-antigens-autoantibodies-methodology-and-clinical-utility/14285/ Autoantibody Screening to Identify Risk for Type 1 DiabetesT1D defines a continuum that begins during an asymptomatic prodrome before the disease manifests clinically. One of the challenges of T1D is identifying persons at high risk before the onset of clinical manifestations by screening for pancreatic β cell autoantibodies. Interventions to delay or prevent the underlying autoantibody-mediated loss of pancreatic β cells are now available to delay or potentially prevent the clinical presentation of T1D as diabetic ketoacidosis and mitigate subsequent, longer-term complications.=

Link to bioRxiv paper: http://biorxiv.org/cgi/content/short/2022.09.29.510196v1?rss=1 Authors: Zhou, J., Greenfield, A., Loudermilk, R., Bartley, C., Tran, B., Zhao, C., Wang, H., Wilson, M., Pleasure, S. Abstract: NMDA receptor autoimmune encephalitis (NMDAR-AE) is characterized by cerebrospinal fluid (CSF)-resident anti-NMDA receptor autoantibodies that cause behavioral and neurologic deficits. Although many symptoms are responsive to immunotherapy, for many patients functionally impairing deficits persist. We used patient-derived GluN1 and GluN2A-specific monoclonal antibodies (mAbs) to interrogate the molecular and circuit basis for persistent sensory-motor deficits following NMDAR-AE. During postnatal development, intracortical injection of either mAb disrupted callosal circuit formation with excess callosal projections in primary somatosensory cortex (S1), although the anti-GluN1 antibody provoked the more severe phenotype. S1 circuit disruption during development results in permanent axon morphology alterations and sensory-motor deficits lasting to adulthood. The severity of sensory-motor deficits was correlated with the severity of axon morphology alterations, and these anatomic changes are associated with sensory-motor behavior deficits similar to those in children NMDAR-AE. Our studies provide a molecular, cellular, and circuit basis for persistent neuropsychiatric deficits in NMDAR-AE. Copy rights belong to original authors. Visit the link for more info Podcast created by PaperPlayer

What is autoimmune-associated epilepsy, and how is it different from acute seizures with an autoimmune cause? How can clinicians best diagnose and treat these conditions? Sharp Waves reporter Dr. Maryam Nabavi-Nouri spoke with Dr. Claude Steriade.Claude Steriade, MD, CM is originally from Quebec City, Canada. She completed medical school at McGill University in Montreal, followed by an adult neurology residency at the University of Toronto. Dr. Steriade then completed a two-year epilepsy fellowship at the Cleveland Clinic before joining the epilepsy center at New York University. Relevant articles:Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: Conceptual definitionsDiscerning the Role of Autoimmunity and Autoantibodies in Epilepsy: A Review --This episode was reported by Dr. Maryam Nabavi-Nouri, and edited and produced by Nancy Volkers.Sharp Waves content is meant for informational purposes only and not as medical or clinical advice.The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Twitter, and Instagram.Contact us with feedback or episode ideas at podcast@ilae.orgILAE website | Facebook | InstagramTwitter feeds: English | French | Japanese | Portuguese | Spanish | ILAE-YES  The International League Against Epilepsy invites you to explore the ILAE Academy: Interactive, practice based online courses for health care professionals who diagnose and treat epilepsy. Find more information at ilae-academy.org. Support the showSharp Waves episodes are meant for informational purposes only, and not as clinical or medical advice.The International League Against Epilepsy is the world's preeminent association of health professionals and scientists, working toward a world where no person's life is limited by epilepsy. Visit us on Facebook, Twitter, and Instagram.

Welcome to OC talks, a podcast series exploring the latest advancements in oncology. I'm your host, Jade Parker, Oncology Central's Senior Editor. In this episode, supported by Sengenics, we will be exploring the importance of autoantibodies in the development of cancer as well as how they can be used in the early detection of tumors. Joining me for this episode is Field Application Scientist Joseph Miseirvitch from Sengenics, a precision medicine company working to improve patient outcomes for physiologically relevant, data-guided decision making.

There's a bit of a misunderstanding in the health world that endometriosis is just a hormone problem, but this line of thinking is incomplete. Hormones can absolutely contribute to the endometriosis picture, but they are not the cause of endometriosis. And part of treating endometriosis should include strategies to support the hormones, though that's not where the support should end. Today on the show Erin speaks with Dr. Lara Briden all about endometriosis and why it's such a complex thing to treat. Tune in to hear Lara dive into the immune side of endometriosis, epigenetics, gut dysbiosis, and how all these things can be interconnected. Erin and Lara also discuss testing options and strategies to treat endometriosis, plus and natural remedies you can try at home and lifestyle factors to consider. This episode is important to hear if you've been struggling with endometriosis or suspect you might have it, have been diagnosed with IBS but think there may be more going on, or if you're a practitioner looking to deepen your understanding on the complexities of endometriosis. In this episode: -Lara Briden is kind of a big deal [2:50] -The misunderstanding with endometriosis [4:02] -Looking at endometriosis as a disease of immune dysfunction [7:25] -Lara's philosophy towards women's physiology and women's health [8:57] -What is endometriosis? [13:26] -Retrograde menstruation [16:20] -Autoantibodies associated with endometriosis [20:31] -The link between endometriosis and GI dysfunction [21:47] -The importance of the immune cells macrophages [23:14] -Focusing on bacteria as part of endometriosis treatment [25:30] -The overlap between SIBO, IBS & endometriosis [28:54] -Epigenetic involvement in endometriosis [31:11] -Visceral sensitivity [37:52] -How hormones like estrogen & progesterone can impact endometriosis [39:41] -Why the pill isn't always the best option for endometriosis [44:34] -Progesterone resistance, and what it means for endometriosis [46:26] -Testing options, natural remedies and treatment strategies [48:46] -The role nickel allergy plays [55:13] -The regulating effects of vitamin A [59:20] -Reducing endometriosis lesions [1:00:22] -What to know about taking iodine [1:01:49] FOR OUR FULL LIST OF LINKS + RESOURCES, HEAD TO: https://www.thefunktionalnutritionist.com/podcast/219-endometriosis-hormone-gut-immune-health-lara-briden

The Journal of Rheumatology's Editor-in-Chief Earl Silverman discusses this month's selection of articles that are most relevant to the clinical rheumatologist. Included is an excerpt from this month's Editor's Picks spotlight interview with authors Gregory McDermott, Ritu Gill, Staci Gagne, Suzanne Byrne, Weixing Huang, Xiaosong Wang, Lauren C. Prisco, Alessandra Zaccardelli, Lily W. Martin, Lucy Masto, Vanessa L. Kronzer, Nancy Shadick, Paul F. Dellaripa, Tracy J. Doyle and Jeffrey A. Sparks about their article "Demographic, Lifestyle, and Serologic Risk Factors for Rheumatoid Arthritis (RA)–associated Bronchiectasis: Role of RA-related Autoantibodies" - doi.org/10.3899/jrheum.211242 This month's selections also include: Mortality Rates in Patients With Ankylosing Spondylitis With and Without Extraarticular Manifestations and Comorbidities: A Retrospective Cohort Study - doi.org/10.3899/jrheum.210909 Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis - doi.org/10.3899/jrheum.210906 Tacrolimus in Patients With Interstitial Pneumonia Associated With Polymyositis or Dermatomyositis: Interim Report of Postmarketing Surveillance in Japan - doi.org/10.3899/jrheum.210322 Gout and Hospital Admission for Ambulatory Care–Sensitive Conditions: Risks and Trajectories - doi.org/10.3899/jrheum.220038 IgG4-related Disease With Destructive Nasal Bone Involvement Leading to Saddle Nose Deformity - doi.org/10.3899/jrheum.200621 To read these, and other full articles visit www.jrheum.org. Music by David Hilowitz

Please go to https://academiccme.com/myapodcast/ and complete the evaluation to receive your CE/CME Credit.

TWiV reviews recent cases of monkeypox, presence of SARS-CoV-2 RNA but not infectious virus in feces, and the association of autoantibodies to interferons with severe COVID-19. Hosts: Vincent Racaniello, Dickson Despommier, Rich Condit, Kathy Spindler, and Brianne Barker Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Monkeypox in MA (ProMed Mail) Possible monkeypox in NYC (NY Times) Occupational monkeypox, Wisconsin (Emerg Inf Dis) SARS-CoV-2 in feces (Nature) IFN autoantibodies and severe COVID-19 (PNAS) Letters read on TWiV 902 Timestamps by Jolene. Thanks! Weekly Picks Dickson – How to grow food on the moon Brianne – APod May 16: Milky Way over French Alp Hoodoos Kathy – Covid Nationwide data visualization Rich – NIH All of Us Research Program Vincent – Physicians Spreading Misinformation on Social Media — Do Right and Wrong Answers Still Exist in Medicine? Listener Pick Lisa – E.H. Danner Museum of Telephony Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv

Please go to https://academiccme.com/myapodcast/ and complete the evaluation to receive your CE/CME Credit.

Main website: https://mehlmanmedical.com/ Instagram: https://www.instagram.com/mehlman_medical/ Facebook: https://www.facebook.com/mehlmanmedical Anchor: https://anchor.fm/mehlmanmedical Audio Qbank - Q306 – A 42F with progressive fatigue See full post on our website: https://mehlmanmedical.com/audio-qbank-q306-a-42f-with-progressive-fatigue

This episode covers autoantibodies!

Dermatomyositis and Autoantibodies by Dr. Andrew L. Mammen. This is part three of a three part series on immune-mediated myopathies and autoantibodies.